Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine

Livia Brusa, Antonio Orlacchio, Vincenzo Moschella, Cesare Iani, Giorgio Bernardi, Nicola Biagio Mercuri

Research output: Contribution to journalArticlepeer-review

Abstract

Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalMovement Disorders
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 15 2009

Keywords

  • Aripiprazole
  • Huntington's disease
  • Neuroleptics
  • Tetrabenazine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine'. Together they form a unique fingerprint.

Cite this